These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

298 related items for PubMed ID: 34529443

  • 21. Discovery and structure-activity relationship of novel diphenylthiazole derivatives as BTK inhibitor with potent activity against B cell lymphoma cell lines.
    Guo X, Yang D, Fan Z, Zhang N, Zhao B, Huang C, Wang F, Ma R, Meng M, Deng Y.
    Eur J Med Chem; 2019 Sep 15; 178():767-781. PubMed ID: 31234030
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Targeting the C481S Ibrutinib-Resistance Mutation in Bruton's Tyrosine Kinase Using PROTAC-Mediated Degradation.
    Buhimschi AD, Armstrong HA, Toure M, Jaime-Figueroa S, Chen TL, Lehman AM, Woyach JA, Johnson AJ, Byrd JC, Crews CM.
    Biochemistry; 2018 Jul 03; 57(26):3564-3575. PubMed ID: 29851337
    [Abstract] [Full Text] [Related]

  • 24. Discovery of 1-Amino-1H-imidazole-5-carboxamide Derivatives as Highly Selective, Covalent Bruton's Tyrosine Kinase (BTK) Inhibitors.
    Ma C, Li Q, Zhao M, Fan G, Zhao J, Zhang D, Yang S, Zhang S, Gao D, Mao L, Zhu L, Li W, Xu G, Jiang Y, Ding Q.
    J Med Chem; 2021 Nov 11; 64(21):16242-16270. PubMed ID: 34672559
    [Abstract] [Full Text] [Related]

  • 25. Discovery of Pteridine-7(8H)-one Derivatives as Potent and Selective Inhibitors of Bruton's Tyrosine Kinase (BTK).
    Dou D, Diao Y, Sha W, Su R, Tong L, Li W, Leng L, Xie L, Yu Z, Song H, Shen Z, Zhu L, Zhao Z, Xie H, Chen Z, Li H, Xu Y.
    J Med Chem; 2022 Feb 10; 65(3):2694-2709. PubMed ID: 35099969
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Discovery of pyrrolo[1,2-a]quinoxalin-4(5H)-one derivatives as novel non-covalent Bruton's tyrosine kinase (BTK) inhibitors.
    Su R, Diao Y, Sha W, Dou D, Yu Z, Leng L, Zhao Z, Chen Z, Li H, Xu Y.
    Bioorg Chem; 2022 Sep 10; 126():105860. PubMed ID: 35661525
    [Abstract] [Full Text] [Related]

  • 28. Optimization of novel reversible Bruton's tyrosine kinase inhibitors identified using Tethering-fragment-based screens.
    Hopkins BT, Bame E, Bell N, Bohnert T, Bowden-Verhoek JK, Bui M, Cancilla MT, Conlon P, Cullen P, Erlanson DA, Fan J, Fuchs-Knotts T, Hansen S, Heumann S, Jenkins TJ, Marcotte D, McDowell B, Mertsching E, Negrou E, Otipoby KL, Poreci U, Romanowski MJ, Scott D, Silvian L, Yang W, Zhong M.
    Bioorg Med Chem; 2019 Jul 01; 27(13):2905-2913. PubMed ID: 31138459
    [Abstract] [Full Text] [Related]

  • 29. A Fast and Clean BTK Inhibitor.
    Gabizon R, London N.
    J Med Chem; 2020 May 28; 63(10):5100-5101. PubMed ID: 32401033
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Discovery of 4,7-Diamino-5-(4-phenoxyphenyl)-6-methylene-pyrimido[5,4- b]pyrrolizines as Novel Bruton's Tyrosine Kinase Inhibitors.
    Xue Y, Song P, Song Z, Wang A, Tong L, Geng M, Ding J, Liu Q, Sun L, Xie H, Zhang A.
    J Med Chem; 2018 May 24; 61(10):4608-4627. PubMed ID: 29715023
    [Abstract] [Full Text] [Related]

  • 32. Combined pharmacophore, virtual screening and molecular dynamics studies to identify Bruton's tyrosine kinase inhibitors.
    Sakthivel S, Habeeb SKM.
    J Biomol Struct Dyn; 2018 Dec 24; 36(16):4320-4337. PubMed ID: 29293382
    [Abstract] [Full Text] [Related]

  • 33. Discovery of a novel BTK inhibitor S-016 and identification of a new strategy for the treatment of lymphomas including BTK inhibitor-resistant lymphomas.
    Song PR, Wan ZP, Huang GG, Song ZL, Zhang T, Tong LJ, Fang Y, Tang HT, Xue Y, Zhan ZS, Feng F, Li Y, Shi WH, Huang YQ, Chen Y, Duan WH, Ding J, Zhang A, Xie H.
    Acta Pharmacol Sin; 2024 Oct 24; 45(10):2163-2173. PubMed ID: 38834683
    [Abstract] [Full Text] [Related]

  • 34. Structure-activity relationship investigation for imidazopyrazole-3-carboxamide derivatives as novel selective inhibitors of Bruton's tyrosine kinase.
    Zhang D, Xu G, Zhao J, Wang Y, Wu X, He X, Li W, Zhang S, Yang S, Ma C, Jiang Y, Ding Q.
    Eur J Med Chem; 2021 Dec 05; 225():113724. PubMed ID: 34391034
    [Abstract] [Full Text] [Related]

  • 35. Next-generation Bruton's Tyrosine Kinase (BTK) Inhibitors Potentially Targeting BTK C481S Mutation- Recent Developments and Perspectives.
    Das D, Wang J, Hong J.
    Curr Top Med Chem; 2022 Dec 05; 22(20):1674-1691. PubMed ID: 35927919
    [Abstract] [Full Text] [Related]

  • 36. Zanubrutinib (BGB-3111), a Second-Generation Selective Covalent Inhibitor of Bruton's Tyrosine Kinase and Its Utility in Treating Chronic Lymphocytic Leukemia.
    Rhodes JM, Mato AR.
    Drug Des Devel Ther; 2021 Dec 05; 15():919-926. PubMed ID: 33688166
    [Abstract] [Full Text] [Related]

  • 37. Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton's Tyrosine Kinase Inhibitor in Early Clinical Development.
    Crawford JJ, Johnson AR, Misner DL, Belmont LD, Castanedo G, Choy R, Coraggio M, Dong L, Eigenbrot C, Erickson R, Ghilardi N, Hau J, Katewa A, Kohli PB, Lee W, Lubach JW, McKenzie BS, Ortwine DF, Schutt L, Tay S, Wei B, Reif K, Liu L, Wong H, Young WB.
    J Med Chem; 2018 Mar 22; 61(6):2227-2245. PubMed ID: 29457982
    [Abstract] [Full Text] [Related]

  • 38. ZYBT1, a potent, irreversible Bruton's Tyrosine Kinase (BTK) inhibitor that inhibits the C481S BTK with profound efficacy against arthritis and cancer.
    Ghoshdastidar K, Patel H, Bhayani H, Patel A, Thakkar K, Patel D, Sharma M, Singh J, Mohapatra J, Chatterjee A, Patel D, Bahekar R, Sharma R, Gupta L, Patel N, Giri P, Srinivas NR, Jain M, Bandyopadhyay D, Patel PR, Desai RC.
    Pharmacol Res Perspect; 2020 Aug 22; 8(4):e00565. PubMed ID: 32790160
    [Abstract] [Full Text] [Related]

  • 39. Mechanisms of Resistance to Noncovalent Bruton's Tyrosine Kinase Inhibitors.
    Wang E, Mi X, Thompson MC, Montoya S, Notti RQ, Afaghani J, Durham BH, Penson A, Witkowski MT, Lu SX, Bourcier J, Hogg SJ, Erickson C, Cui D, Cho H, Singer M, Totiger TM, Chaudhry S, Geyer M, Alencar A, Linley AJ, Palomba ML, Coombs CC, Park JH, Zelenetz A, Roeker L, Rosendahl M, Tsai DE, Ebata K, Brandhuber B, Hyman DM, Aifantis I, Mato A, Taylor J, Abdel-Wahab O.
    N Engl J Med; 2022 Feb 24; 386(8):735-743. PubMed ID: 35196427
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.